Orbicular Pharmaceutical Technologies, located in Hyderabad, India, and Apotex have received tentative approval from the US Food and Drug Administration (FDA) for a generic version of Ozempic (semaglutide injection). This approval signifies Orbicular's entry into the complex peptide generic market, which is largely dominated by Novo Nordisk's Ozempic. The FDA's tentative approval indicates that the generic product meets the necessary quality, safety, and efficacy standards; however, it cannot be marketed in the US until patent or exclusivity barriers are resolved. Orbicular collaborated with Apotex for the development of the semaglutide injection, contributing to formulation development and analytical work. Once final approval is granted, Apotex will handle the marketing and distribution of the product in the US. M S Mohan, managing director of Orbicular, emphasized the rigorous scientific and analytical efforts required to achieve technical equivalence for such complex peptide products. The collaboration aligns with Apotex's strategy to broaden access to lower-cost peptide therapies in the US market, as demand for GLP-1 therapies continues to grow.